BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 30952710)

  • 1. P-Glycoprotein Overexpression Is Associated With Cisplatin Resistance in Human Osteosarcoma.
    He C; Sun Z; Hoffman RM; Yang Z; Jiang Y; Wang L; Hao Y
    Anticancer Res; 2019 Apr; 39(4):1711-1718. PubMed ID: 30952710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long non-coding RNA ROR regulated ABCB1 to induce cisplatin resistance in osteosarcoma by sponging miR-153-3p.
    Cheng FH; Zhao ZS; Liu WD
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(17):7256-7265. PubMed ID: 31539112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of beclin1 affects the chemotherapeutic sensitivity of osteosarcoma.
    Wu W; Li W; Zhou Y; Zhang C
    Int J Clin Exp Pathol; 2014; 7(10):7114-22. PubMed ID: 25400807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCN2 enhances resistance to cisplatin-mediating cell apoptosis in human osteosarcoma.
    Tsai HC; Huang CY; Su HL; Tang CH
    PLoS One; 2014; 9(3):e90159. PubMed ID: 24637722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
    Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
    Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oestrogen-related receptor alpha mediates chemotherapy resistance of osteosarcoma cells via regulation of ABCB1.
    Chen Y; Zhang K; Li Y; Guo R; Zhang K; Zhong G; He Q
    J Cell Mol Med; 2019 Mar; 23(3):2115-2124. PubMed ID: 30609256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated H3K27me3 levels sensitize osteosarcoma to cisplatin.
    He C; Sun J; Liu C; Jiang Y; Hao Y
    Clin Epigenetics; 2019 Jan; 11(1):8. PubMed ID: 30651137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.
    Liu T; Li Z; Zhang Q; De Amorim Bernstein K; Lozano-Calderon S; Choy E; Hornicek FJ; Duan Z
    Oncotarget; 2016 Dec; 7(50):83502-83513. PubMed ID: 27835872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining GRP78 suppression and MK2206-induced Akt inhibition decreases doxorubicin-induced P-glycoprotein expression and mitigates chemoresistance in human osteosarcoma.
    Xia YZ; Yang L; Xue GM; Zhang C; Guo C; Yang YW; Li SS; Zhang LY; Guo QL; Kong LY
    Oncotarget; 2016 Aug; 7(35):56371-56382. PubMed ID: 27486760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-340 alleviates chemoresistance of osteosarcoma cells by targeting ZEB1.
    Yan H; Zhang B; Fang C; Chen L
    Anticancer Drugs; 2018 Jun; 29(5):440-448. PubMed ID: 29494357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA‑22 regulates autophagy and apoptosis in cisplatin resistance of osteosarcoma.
    Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Sun L; Sun C; Feng W; Guo SB
    Mol Med Rep; 2020 Nov; 22(5):3911-3921. PubMed ID: 33000186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma.
    Fan GT; Ling ZH; He ZW; Wu SJ; Zhou GX
    Biochem Biophys Res Commun; 2021 May; 554():214-221. PubMed ID: 33813077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PLK2 modulation of enriched TAp73 affects osteogenic differentiation and prognosis in human osteosarcoma.
    Li W; Zhang X; Xi X; Li Y; Quan H; Liu S; Wu L; Wu P; Lan W; Shao Y; Li H; Chen K; Hu Z
    Cancer Med; 2020 Jun; 9(12):4371-4385. PubMed ID: 32349184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.
    He C; Liu C; Wang L; Sun Y; Jiang Y; Hao Y
    Cell Death Dis; 2019 Jan; 10(2):65. PubMed ID: 30683853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TFAP2C-mediated LINC00922 signaling underpins doxorubicin-resistant osteosarcoma.
    Gu Z; Zhou Y; Cao C; Wang X; Wu L; Ye Z
    Biomed Pharmacother; 2020 Sep; 129():110363. PubMed ID: 32563982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism of drug resistance.
    Avnet S; Lemma S; Cortini M; Pellegrini P; Perut F; Zini N; Kusuzaki K; Chano T; Grisendi G; Dominici M; De Milito A; Baldini N
    Oncotarget; 2016 Sep; 7(39):63408-63423. PubMed ID: 27566564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced Stim1 expression is associated with acquired chemo-resistance of cisplatin in osteosarcoma cells.
    Sun X; Wei Q; Cheng J; Bian Y; Tian C; Hu Y; Li H
    Hum Cell; 2017 Jul; 30(3):216-225. PubMed ID: 28326487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PAXX is a novel target to overcome resistance to doxorubicin and cisplatin in osteosarcoma.
    Ma W; Yang L; Liu H; Chen P; Ren H; Ren P
    Biochem Biophys Res Commun; 2020 Jan; 521(1):204-211. PubMed ID: 31640855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene.
    Pu Y; Zhao F; Li Y; Cui M; Wang H; Meng X; Cai S
    BMC Cancer; 2017 Jan; 17(1):45. PubMed ID: 28073349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
    Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
    J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.